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Abstract 
 
Port-a-Cath© (PAC) are totally implantable devices that offer an easy and long term access to venous 
circulation. They have been extensively used for intravenous therapy administration and are 
particularly well suited for chemotherapy in oncologic patients. Previous comparative studies have 
shown that these devices have the lowest catheter-related bloodstream infection rates among all 
intravascular access systems. However, bloodstream infection (BSI) still remains a major issue of port 
use and epidemiology data for PAC-associated BSI (PABSI) rates differ strongly depending on studies. 
Also, current literature about PABSI risk factors is scarce and sometimes controversial. Such 
heterogeneity may depend on type of studied population and local factors. Therefore, the aim of this 
study was to describe local epidemiology and risk factors for PABSI in adult patients in our tertiary-
care university hospital. 
We conducted a retrospective cohort study in order to describe local epidemiology. We also 
performed a nested case-control study to identify local risk factors of PABSI. We analyzed medical 
files of adult patients who had a PAC implanted between January 1st, 2008 and December 31st, 2009 
and looked for PABSI occurrence before May 1st, 2011 to define cases. 
Thirty nine PABSI occurred in this population with an attack rate of 5.8%. We estimated an incidence 
rate of 0.08/1000 PAC-days using the case-control study. PABSI causative agents were mainly Gram 
positive cocci (62%). We identified three predictive factors of PABSI by multivariate statistical 
analysis: neutropenia on outcome date (Odds Ratio [OR]: 4.05; 95% confidence interval [CI]:1.05-
15.66; p=0.042), diabetes (OR: 11.53; 95% CI: 1.07-124.70; p=0.044) and having another infection 
than PABSI on outcome date (OR: 6.35; 95% CI: 1.50-26.86; p=0.012). Patients suffering from acute 
or renal failure (OR: 4.26; 95% CI: 0.94-19.21; p=0.059) or wearing another invasive device (OR: 2.99; 
95% CI: 0.96-9.31; p=0.059) did not have a statistically increased risk for developing a PABSI 
according to classical threshold (p<0.05) but nevertheless remained close to significance.  
Our study demonstrated that local epidemiology and microbiology of PABSI in our institution was 
similar to previous reports. A larger prospective study is required to confirm our results or to test 
preventive measures. 
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Note préliminaire: il a été convenu avec le tuteur que mon travail d’écriture consisterait à produire 
un article possiblement publiable. Partant de ce principe, certaines images tirées d’autres études ont 
été ajoutées pour le travail de master mais ne feraient pas partie d’une éventuelle publication. Elles 
sont indiquées par un « S. » pour « supplementary » devant la légende de figure ou de table.  
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Introduction 
Totally implantable venous access port (or Port
devices that provide an easy and permanent access to large veins. They have been introduced since 
the early 1980s and are now largely used in oncology patients who require long term 
with repeated venous punctures. These devices are also well suited for delivery of other therapies 
such as parenteral nutrition, blood transfusion or intravascular fluids 
implanted annually in the USA has been estimated as more than 5 millions in 2000 
even higher nowadays. 
PACs are composed of a subcutaneous chamber with a self
by a needle through the intact skin 
surgically inserted beneath the skin under local anesthesia. The preferred implantation site is below 
the right clavicle in order to access the superior vena cava thro
jugular vein (3) (see  
S. Figure 1). 
 
S. Figure 1 : Scheme of Port-a-Cath© insertion site and components
Left: Port-a-Cath© insertion site under right 
Right: front view of Port-a-Cath© implanted beneath skin and punctured.
Modified from www.cancerhelpuk.org 
 
PACs have several advantages for long term use compared to other central ve
they are more comfortable for patients as they require less nursing (catheter changing, flushing…), 
are less visible and are less impeding for daily life activities such as showers or swimming. Moreover, 
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-a-Cath©, named PAC thereafter) are intravascular 
(1). The number of PACs 
-sealing membrane that can be accessed 
and are connected to a central venous catheter
ugh the subclavian or the internal 
 
clavicle with catheter access to right subclavian vein and superior vena cava. 
 
nous catheters. First, 
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chemotherapy 
(2) and must be 
. The device is 
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their access to large vessels allows rapid dilution of potentially toxic infusates such as chemotherapy 
and thus minimizes venous damages (1). 
In a large comparative review (4), PACs had the lowest catheter-related bloodstream infection 
(CRBSI) rates among all intravascular access systems. However, bloodstream infection (BSI) still 
remains a major issue of port use and epidemiology data for PAC-associated BSI (PABSI) rates differ 
strongly depending on studies (see Table 1). Other complications include short-term complications 
related to surgery and long-term complications such as port-related venous thrombosis, catheter 
occlusion or catheter fragmentation (1,5). 
 
Table 1 : Epidemiology data for Port-a-Cath©-associated bloodstream infections from different studies. 
Data come from some recent studies focusing on Port-a-Cath© systems and are compared together without concern for 
studied population. Research type is also detailed. 
Reference Type of study Attack rate Incidence rate 
Chang et al. (6) Retrospective 8.9% 0.26/1000 catheter-days 
Dal Molin et al. (7)  Prospective - 0.04/1000 catheter-days 
Maki et al. (4) Review of 17 studies 3.6-4.0% 0.2/1000 catheter-days 
Sakamoto et al. (8) Prospective 1.4% - 
Teichgräber et al. (9) Retrospective 5.1% 0.145/1000 catheter-days 
Touré et al. (10) Prospective 13.0% 0.76/1000 catheter-days 
Yoshida et al. (11) Retrospective - 2.81/1000 days of use 
 
 
The general mechanism of intravascular devices colonization by microorganisms is achieved by 
biofilm formation on synthetic material and dissemination of free-floating forms along the catheter 
(see S. Figure 2). Colonization can occur already 24h after device insertion (12). For PACs, the main 
sources of infection are thought to be intraluminal colonization of the chamber during iterative 
injections and extraluminal colonization by skin flora from patient or medical staff. This second 
mechanism is believed to be less frequent in long term infections since PACs are inserted beneath 
intact skin (13). Contamination of administrated infusate is also a rare possibility. PAC infection can 
remain local and cause a subcutaneous pocket infection at implantation site or eventually spread to 
bloodstream and become systemic (14). Using ROC curves in a retrospective study, Yoshida et al. 
determined that the safety cutoff before PABSI was 33 utilization-days (11).  The main 
microorganisms responsible for PAC infections are Staphylococcus epidermidis and other coagulase-
negative staphylococci, Staphylococcus aureus and Candida species (14). Gram-negative bacilli are 
also causative agent of nosocomial PABSI (15). 
 
S. Figure 2 : Scanning electron micrograph of a 
Staphylococcus biofilm on the inner surface of a 
needleless connector. Photograph by Janice Carr, Centers 
for Disease Control and Prevention, Atlanta, GA USA. 
www.cdc.gov 
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Once a PABSI is suspected empirical antibiotic therapy is prescribed depending on the likely 
pathogen, severity of patient’s illness and patient co-morbidities. It is then adapted to the cultured 
pathogen. Duration of treatment and decision between PAC removal or salvage depend on PABSI 
complications and causal pathogen. In general, PAC can be retained in uncomplicated coagulase-
negative staphylococci, enterococci and some Gram-negative bacilli infections (17). 
According to Raad et al. (15), BSI related to intravascular devices have an estimated attributable 
mortality ranging from 12% to 25% in critically ill patients, although this point remains controversial 
(14). To our knowledge, no attributable death has been reported for PABSI, but this point has been 
only little assessed. Complications of PABSI result in an increased morbidity. These include severe 
sepsis or septic shock, infectious metastasis (infectious endocarditis, septic arthritis, osteomyelitis, 
organ abscess), PAC removal with potential therapy delay or cancelling (13). Biffi et al. (18) have 
estimated an averaged increased cost related to PABSI ranging from $1145 to $2141 per patient. 
According to IDSA guidelines, classical risk factors for catheter-related BSI comprise the type of 
intravascular device, the type of and intended use for the catheter, the insertion site, the experience 
and education of the individual who installs the catheter, the frequency with which the catheter is 
accessed, the duration of catheter placement, the characteristics of the catheterized patient, and the 
use of proven preventative strategies (17). Studies focusing on PABSI predictive factors found in the 
literature are scarce and sometimes controversial. The cumulative number of utilization-days 
significantly increases the risk of PABSI. Patients who receive parenteral nutrition have been shown 
to have significantly higher rates of PABSI than with other uses. Palliative care administered 
immediately after PAC implantation also correlates with increased PABSI. The significant factors of 
patient’s condition that have been identified are neutropenia and preexisting sepsis. The type of 
primary illness may play a role as well, since colorectal and pancreatic cancers are thought to 
increase the risk of PABSI compared to other primary malignancy sites. On the other hand, types of 
port system or insertion site localizations (arm vs. subclavian) are not associated with significantly 
different rates of infection (3,4,6,7,11,19–21).  
Some of these potential risk factors are still debated and need further evidence. Also, research 
concentrating on PAC-carrying populations may not define the same predictive factors for BSI than 
previous studies on other catheter types. Moreover and as already shown above, reported 
epidemiology data is inconsistent. Some reviews show even important variations in incidence ranges 
without further precision (Kurul et al. : 2.4-16.0% (3); Jordan et al. : 2.6-27% (5); Biffi et al. : 0-22% 
(18)). This variability could be explained by definition heterogeneity of PABSI and differences in 
studied populations or even by differences in local management of risk factors and prevention 
strategies implementation. Currently, there is no data on PABSI epidemiology and local risk factors 
available in our institution. The aim of this study was thus to describe local epidemiology and risk 
factors for PABSI in adult patients in a tertiary-care university hospital. This could help our institution 
and others to better prevent PABSI and decrease related morbidity. 
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Patients and methods 
 
We conducted a retrospective cohort study in a 1020-bed tertiary care university hospital in 
Switzerland. We included all patients aged more than 18 who had a PAC implanted between January 
1st, 2008 and December 31st, 2009 according to the operation theatre statistics. End of follow-up for 
the whole cohort was set on May 1st, 2011.  
This study was approved by our local research ethics comity (Commission cantonale d’éthique de la 
recherche sur l’être humain, Lausanne, Switzerland). 
 
Attack rate and definition of PABSI 
In order to calculate the attack rate of PABSI, we looked for positive blood cultures in included 
patients from January 1st, 2008 to May 1st, 2011 in the microbiology information system. We 
considered only the first case of PABSI for each patient. Since no universal definition of PABSI has 
been established yet, we based our definition criteria on different guidelines (14,17,22) and adapted 
them to available data in the electronic files, especially in the infectious diseases consilium report 
when available (see Table 2). 
 
Table 2 : Minimal microbiological criteria for definition of Port-a-Cath©-associated bloodstream infection 
In all situations presented below, the bloodstream infections was considered while a Port-a-Cath© (PAC) was implanted 
and had no other apparent source than the PAC. Microorganisms of the same species collected from separate blood 
cultures and having the same antibiotic susceptibility profile were considered as belonging to the same strain.  
PAC: Port-a-Cath©; PABSI: PAC-associate bloodstream infection 
 
 Blood cultures yielding a common skin contaminant
1
  Blood cultures yielding other results 
Possible 
PABSI 
> 2 sets of blood cultures drawn from the PAC yielding 
the same bacterial strain 
OR 
Positive culture of 1/1 set drawn from the PAC AND 
presence of fever not explained otherwise. 
Positive culture of > 1 set of blood 
culture drawn from the PAC 
Probable 
PABSI 
> 2 sets of blood cultures, with at least one drawn from 
a peripheral vein, yielding the same bacterial strain 
Positive culture of > 1 set of blood 
culture drawn from a peripheral vein 
Definite 
PABSI 
Probable PABSI
2
 confirmed by a PAC culture that yielded the same pathogen. 
 
1
 Including diphteroids, Bacillus spp., coagulase-negative staphylococci and micrococci 
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Features of PABSI 
The first day of PABSI was defined as the date of the first PABSI-defining blood culture. The time to 
PABSI was defined as the time elapsed between the PAC implantation and the first day of PABSI. The 
duration of PABSI was defined as the time elapsed from the first day of PABSI and the first day with 
complete culture negation when available, or the day of end of symptoms or death.  
A hospital-onset PABSI was defined as a PABSI occurring 48 hours or more after hospital admission. A 
local PAC infection was suggested by the presence of typical inflammatory signs (redness, swelling, 
pain, purulent exsudate) at the PAC implantation site. We used the criteria of Annane et al (23) to 
define septic syndrome.  
We defined PABSI complications as PAC removal, metastatic infectious focus, transfer to ICU or death 
when they were a direct consequence of PABSI. Deaths were reported in both populations if they 
occurred between the implantation date and 15 days after the outcome date; this endpoint was 
chosen in order to include deaths probably attributable to PABSI in the case group. 
Risk factors  
The risk factors for developing a PABSI were analyzed using a nested case-control study.  
We defined controls as adult patients who had a PAC implanted during the study period and who did 
not develop a PABSI until the end of follow-up. For each PABSI case of the cohort, we selected the 
control patient who had the closest implantation date, and who had medical information available 
on a reference date which was set on the date of the PABSI for the corresponding case plus or minus 
90 days. Reference dates in controls as well as dates of PABSI in cases are called outcome dates 
thereafter. Control patients were excluded when their PAC was removed before the respective 
outcome date, and replaced by the next most suitable control. Follow-up time was defined as the 
time from implantation to PABSI in cases and as the time from implantation to death, PAC removal or 
end date of follow-up in controls. 
We looked for an association of PABSI with the following covariates documented on outcome dates: 
PAC in use (defined as the performance of nursery care such as needle or dressing change), presence 
of another invasive device, anemia (hemoglobin lower than 130 g/L for men or lower than 120 g/L for 
women), neutropenia (counts lower than 1800 neutrophils/µl), thrombocytopenia (counts less than 
150 G/L), overweight (body mass index higher than 25.0 kg/m2), history of smoking or history of 
alcohol abuse, diabetes mellitus of both types, renal failure and concomitant infection. We also 
recorded any medical condition mentioned in patient history. We also collected date about 
chemotherapy, radiotherapy and glucocorticoids or antacids administrations within 30 days before 
the outcome date.  
Statistical analyses 
We analyzed our data using STATA® 12.0 software (StataCorp, College Station, TE). We compared 
covariates using Fisher's exact test for categorical variables, and Student’s t-test for continuous 
variables. Covariates associated with PABSI at a p-level of 0.2 or less were candidates for the building 
of a multivariate logistic regression model. We then tested all covariates not retained in the model 
for possible confounding.  
 Master thesis –F. Desgranges 
Results 
 
Between January1st, 2008 and December 31st, 2009, a total of 670 PACs were implanted in 654 
patients. Thirty-nine PABSI were de
5.8%. This diagnosis was referred as possible in 19 patients (4
and as definite in 4 patients (10%). Sixty
microbiology database but did not meet the PABSI criteria. The depicted flow
presented in Figure 1. Median time to PABSI was 179 days (range 1
analysis for PABSI occurrence in cases is shown in 
Microbiology results of blood cultures are shown in 
Clinical characteristics of PABSI are summarized in 
following infection (74%), which are further detailed in the table. Death was clearly attributable to 
PABSI in one case, whereas PABSI possibly contrib
 
Figure 1 : Study flow chart 
PAC: Port-a-Cath© PABSI: Port-a-Cath©
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Table 3. 
Table 4. Twenty-nine patients had complications 
uted to death in 6 other cases. 
-associated bloodstream infection 
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Figure 2 Time to Port-a-Cath©-associated bloodstream infection analysis 
Cumulative PABSI-free estimate over time illustrated by Kaplan-Meier time-to-event analysis 
 
 
Table 3 : Distribution of pathogens isolated from blood 
cultures in the Port-a-Cath©-associated bloodstream 
infection group 
 
Microorganisms N % 
Gram-positive cocci 24 61.5 
Coagulase-negative staphylococci 14 35.9 
Staphylococcus aureus 6 15.4 
Enterococcus spp 3 7.7 
Finegoldia mana 1 2.6 
   
Gram-negative bacilli 9 23.1 
Enterobacter spp 4 10.3 
Klebsiella pneumoniae 1 2.6 
Pseudomonas fluorescens 1 2.6 
Stenotrophomonas maltophilia 1 2.6 
Escherichia coli 1 2.6 
Proteus mirabilis 1 2.6 
   
Gram-positive bacilli 2 5.1 
Listeria monocytogenes 1 2.6 
Achromobacter xylosoxidans 1 2.6 
   
Candida albicans 1 2.6 
Mixed flora 3 7.7 
Table 4 : Clinical characteristics of Port-a-Cath©-
associated bloodstream infection 
Cumulative counts and percentages of cases presenting 
each characteristic are shown. PABSI: Port-a-Cath©-
associated bloodstream infection 
Periods related to PABSI Days Range 
Median time to PABSI 179 1-1045 
Median duration of PABSI 4 1-36 
Median duration of antibiotic therapy 13 0-42 
 
Infections characteristics N % 
Hospital onset 24 61.5 
Local infection signs 6 15.4 
Septic syndrome diagnosis 16 41.0 
Sepsis 11 28.2 
Severe sepsis 4 10.3 
Septic shock 1 2.6 
 
Complications of PABSI N % 
Cases with complications 29 74.4 
PAC removal 23 59.0 
Infection secondary spread 3 7.7 
Cardiac decompensation 2 5.1 
Transfer to ICU 4 10.3 
Attributable death 7 17.9 
Definite 1 2.6 
Possible 6 15.4 
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Nested case-control study 
Median follow-up time of our case-control study was 406 days per PAC (range: 1-1213) for a total 
time of 38’982 days. Descriptive data of the study groups are shown in Table 5. Time-to-event 
analysis for PAC maintaining in both groups is illustrated in Figure 3. Results of unilateral statistical 
analysis for PABSI potential risk factors are presented in Table 6. 
 
Figure 3 : Time to Port-a-Cath© removal analysis in cases and controls groups 
Cumulative probability of PAC maintaining over time in cases (red line) and controls (black line) illustrated by Kaplan-Meier 
time-to-event analysis is shown. 
 
 
Table 5 : Descriptive characteristics for both groups 
Cumulative counts of patient presenting condition in each group are shown. P-values were calculated by Fisher's exact test 
for categorical variables, and Student’s t test for continuous variables.  PAC: Port-a-Cath©; CRF: Chronic renal failure. 
Covariates Cases Controls P value 
Patients number 39 39 
 
Sex (M/F) 21/18 17/22 0.820 
Mean age, years (range) 59 (22-84) 58 (29-77) 0.592 
Deaths during PAC carriage 10 7 1.000 
PAC removal 23 3 <0.001 
Mean hospital stay, days (range) 42 (0-209) 9 (0-48) <0.001 
    
Reason for PAC use 
   
Chemotherapy 37 38 1.000 
Solid tumor 30 33 1.000 
Hematological malignancy 7 5 1.000 
Nutrition - 1 1.000 
Vascular access in CRF 2 - 1.000 
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Table 6 : Univariate analysis results for potential risk factors. 
Cumulative counts and proportion of patient presenting the following conditions in each group and results of statistical 
comparisons are shown for unilateral 2-sided Fisher’s exact test. PAC: Port-a-Cath© 
 
Potential risk factors Cases, n (%) Controls, n (%) P value 
PAC in use on outcome date 32 (82.1) 20 (66.7) 0.019 
Anemia 38 (97.4) 31 (79.5) 0.029 
Neutropenia 12 (31.6) 5 (12.8) 0.058 
Thrombocytopenia 14 (35.9) 9 (23.1) 0.321 
Diabetes 5 (12.8) 1 (2.6) 0.200 
Overweighted 24 (61.5) 24 (61.5) 1.000 
History of smoking 11 (31.4) 17 (50.0) 0.145 
History of alcohol misuse 10 (27.0) 7 (18.9) 0.581 
Renal failure 10 (25.6) 3 (7.7) 0.065 
Other infection 14 (35.9) 3 (7.7) 0.005 
Recent chemotherapy 25 (64.1) 25 (64.1) 1.000 
Recent radiotherapy 10 (25.6) 7 (18.0) 0.584 
Recent use of 
glucocorticoids 
10 (25.6) 5 (12.8) 0.250 
Use of antacids 22 (56.4) 15 (38.5) 0.173 
Other invasive device 17 (43.6) 10 (25.6) 0.153 
 
 
Multivariate analysis 
Nine potential risk factors were retained for multivariate modeling and were compared for 
confounding effects. This analysis yielded three independent predictive factors for PABSI that were 
statistically significant (p-value<0.05). Two other factors were close to significance (p-value<0.06) and 
were also included in the final model (see Table 7). 
 
Table 7 : Multivariate analysis of potential risk factor for PAC-associated bloodstream infections 
These results were obtained by multivariate logistic regression model. Odds ratios are shown with 95% confidence interval 
(95% CI) and p-values. * P-value <0.05 
 
Potential risk factors Odds Ratio 95% CI P-value 
Neutropenia 4.05 1.05 15.66 0.042* 
Diabetes 11.53 1.07 124.70 0.044* 
Other infection 6.35 1.50 26.86 0.012* 
Renal failure 4.26 0.94 19.21 0.059 
Other invasive device 2.99 0.96 9.31 0.059 
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Discussion 
 
We conducted a retrospective study to investigate local epidemiology and risk factors of PABSI in our 
university tertiary-care hospital. According to current evidence, PACs have the lowest bloodstream 
infection rates among intravascular devices (4,14,17,22). In this cohort, 39 patients developed a 
PABSI on 670 PAC implantations, thus representing an attack rate of 5.8%. Assuming that mean 
follow-up time in control group is representative of the remaining cohort, we estimated an incidence 
rate of 0.08/1000 PAC-days. Although, available data is inconsistent in literature, our results are 
similar to previous studies (4,6–11) (see Table 1). Compared to these studies, our attack rate is in the 
middle range (1.4-13%), while our extrapolated incidence rate is in the lower values (0.04-0.76/1000 
catheter-days). We possibly had a longer follow-up time in our case-control study than in these 
reports. As shown by Kaplan-Meier time-to-event analysis, PABSI’s probability is high at the 
beginning of PAC carriage (see Figure 2). In fact, the median time to PABSI in our study is 179 days 
which represents 17% of our longest time to PABSI (1045 days). This agrees with other reports which 
showed that risk of PABSI decreases over time of catheterization (3) and that intravascular devices 
are rapidly colonized after implantation (12). 
Pathogen epidemiology for PABSI depends on local community and hospital flora, type of studied 
population, type of intravascular catheter and type of PAC’s use (14,15,22,24). Nevertheless, our 
findings are consistent with current reviews as the first isolated causative agents of PABSI were 
coagulase-negative staphylococci (36%) and Staphylococcus aureus (15%). We found a relatively high 
proportion of Gram-negative bacilli (23%) that may be a consequence of a high proportion of 
hospital-onset PABSI in our population (61%); in fact, 8 patients over 9 hospital-onset PABSI were 
infected by Gram-negative bacilli among which we retained 3 possible, 3 probable and 2 definite 
diagnosis of PABSI (data not shown). This is in line with a previous report (25). We recorded only one 
candidemia (2.6%) which corroborates expected proportion (24). 
Complications of PABSI occurred in 29 cases (74%). In cases group, PAC was removed in 23 patients 
(59%) and was always ablated because of PABSI. Thus, PABSI was the cause of the significantly higher 
number of PAC extractions in cases compared to controls (p<0.001). This is further illustrated by 
Kaplan-Meier analysis (see Figure 3) with a 0.5 cumulative probability of PAC removal after 930 days 
in cases and a maximal cumulative probability of 0.94 after 1045 days in controls. Since PABSI caused 
an earlier PAC removal in cases, it may have caused a prejudice in this group, especially in pre-
established therapy program. Moreover, among patients who had their PAC removed, 20 cases and 2 
controls were utilizing their PAC on outcome date (87% and 67%, respectively). Nevertheless, PACs 
were replaced only in 2 patients before the end of follow-up and we do not know reasons for not 
implanting new PACs in others (patient’s health state or refusal, no more utility of PAC, change in 
therapy program…). Therefore, we cannot conclude whether removal yielded to greater morbidity.  
PABSI was responsible for secondary infection spread in 3 cases (7.7%), cardiac decompensation in 2 
cases (5.1%) and transfers to ICU in 4 cases (10.3%), which certainly generated extra care and costs. 
On 10 deaths reported in the cases’ group, PABSI was responsible for one death and contributed to 
death of 6 other patients. The cumulative count of deaths in case group was not statistically different 
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than in control group, though.  If we consider that the control group is a representative sample of the 
whole cohort, our study would therefore show no increased mortality related to PABSI in agreement 
with other studies on intravascular devices (14).  
We performed a nested case-control study without pair matching other than similar time to PABSI in 
cases and to an analogous date in controls. Since this represents an artificial matching, it is 
reasonable to accept that the control group was generated randomly and is thus representative of 
the whole cohort. In a recent study, Touré et al. (10) excluded PABSI occurring before day 14 after 
catheter insertion from their analysis in order to eliminate catheter contamination at time of 
insertion. As previously mentioned, catheter colonization is present as early as 24h after insertion 
(12). Since we matched cases and controls on similar time to outcome, we decided to include early 
PABSI as well in our study groups. This situation occurred in 5 cases (range: 1-13 days) and 5 controls 
(range: 5-13 days) 
The population of the case-control study turned out to be mainly composed of patients with solid 
malignancies (77% in cases versus 84% in controls) and PACs were mainly used for chemotherapy 
injections (95% in cases versus 97% in controls). Both populations were then not different in terms of 
type of PAC use and underlying diseases. Consequently, we did not find any correlation between 
these factors and PABSI. This is inconsistent with current literature since hematological malignancies 
are considered as a risk factor for CRBSI (3). To our knowledge, this factor was never assessed for 
PACs only. It is important to note that although parenteral nutrition has been validated as a risk 
factor for PABSI, we could not investigate this point since only one patient was concerned in our 
nested study. Also, we did not assess the predictive value of certain types of cancers as we did not 
categorize them more precisely.  
No significant difference was found for sex or age between both groups, meaning that these factors 
are not predictive for PABSI occurrence. This statement is in agreement with available literature 
(3,14,22), although one report showed that patients aged of more than 55 years old have a higher 
incidence rate of PABSI (10).  
We found that neutropenia is an independent predictive factor for PABSI (p=0.042). Neutropenia 
results in an immune defect that has been known for a long time to increase infection rates (16). 
Grade 4 neutropenia (i.e. less than 500 neutrophils/µl) was already defined as a risk factor for CRBSI 
(3). Here we show that a higher threshold of neutropenia, defined as 1800 neutrophils/µl in our 
institution, is already significant for PABSI occurrence. When available, overall means of cumulative 
neutropenia time during time to outcome were calculated but were not statistically different 
between cases and controls (5.6 days (range: 0-63) in cases vs. 4.8 days (range: 0-53) in controls, 
p=0.78). Lack of a competent immunity may result in an easier proliferation of pathogens that 
already colonize PAC lumen or catheter tip. Interestingly, no other source of immunosuppression (i.e. 
recent use of chemotherapy, radiotherapy or glucocorticoids) showed any statistical difference 
between groups. Other hematological deficiencies on outcome date (i.e. anemia and 
thrombocytopenia) were not retained as predictive factors in our analysis. 
The population for our comparative analysis comprised 7.7% of diabetic patients which is similar to 
local incidence of diabetes mellitus (around 5%) (27). Diabetes mellitus (DM) was defined as an 
independent risk factor for PABSI in multivariate (p=0.044). Current evidence states that 
hyperglycemia leads to phagocyte dysfunction through various mechanisms (26). It also favors 
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Candida and other fungal species proliferation. Many common infections, such as skin and soft 
tissues infections, are more common in diabetic population (28). The role of diabetes in PABSI 
remains controversial, though, and needs further investigation. Indeed, Yoshida et al. (11) compared 
patients with PABSI to controls and did not retain DM as a predictive factor (OR adjusted: 1.026; 95% 
CI: 0.494-2.130; p=0.945). Similarly, Touré et al. (21) recently showed that diabetes did not 
significantly play a role in BSI in a PAC-carrying population with a DM prevalence of 21.3% 
(cumulative incidences of PABSI : 12.7% in controls vs. 5.9% in DM1, p=0.70; vs. 19.7% in DM2, 
p=0.17, respectively). 
Interestingly, cases with documented infection on outcome date caused by a different pathogen and 
in another location than the PAC were more at risk for PABSI than controls (p=0.012). This may show 
a correlation between these two variables rather than a causative effect. Indeed, the presence of 
another infection may be a marker of patient’s immune system vulnerability and repeated careful 
examination of PAC insertion site should then be established. However, we cannot conclude about 
the usefulness to introduce antibiotics that cover usual PABSI pathogens in this situation, as systemic 
antibiotic prophylaxis does not decrease the incidence of catheter-related BSI (22). Interestingly, this 
risk factor was also pointed out by statistical analysis in another recent study but was not further 
discussed (10). In a same idea, we found that cases had a longer mean hospital stay around outcome 
date than controls (42 days versus 9 days, p<0.001). This variable includes hospitalization time before 
and after outcome date and may thus correlate with PABSI occurrence in two ways. It indicates a 
poorer health condition in case group, resulting either in longer hospitalizations and making cases 
more vulnerable to PABSI or in a longer time needed for restoring after PABSI. 
Acute and chronic renal failures are thought to increase susceptibility to infection via uremic 
syndrome (29). Yoshida et al. showed no significant difference for PABSI due to renal disease but this 
designation was not further explained. Here we found that renal failure had no impact in PABSI 
occurrence according to classical p-value threshold, but nevertheless remained close to significance 
(p=0.059). The role of this variable and its related pathophysiology may be elucidated by specifying 
uremia levels in further research. This data was not routinely available in our cohort. 
Many patients had another catheter or invasive device than the PAC on outcome date (44% in cases 
vs. 26% in controls). We hypothesized that this intravascular equipment could be an entry for 
pathogen colonization. Following the PABSI criteria that we established, other CRBSI have been 
excluded. Nevertheless they could remain a source of blood seeding and colonization of other 
localizations, such as PAC’s catheter tip or chamber.  Carrying another invasive device was not 
considered as a risk factor by multivariate analysis, though (p=0.059). 
Most patients had their PAC in use on outcome date (82% in cases vs. 67% in controls). This factor 
was not retained in our multivariate analysis, although it may remain decisive for PABSI occurrence. 
As explained above, colonization and spread on PAC material is a slow process and is most certainly 
due to repeated punctures through its membrane. Therefore, the cumulative number of punctures 
or utilization-days may be a more relevant factor as demonstrated by Touré et al. (10). 
Unfortunately, we were not able to reliably determine these variables due to inconsistent 
information in medical files. 
PABSI were subdivided in degrees of diagnosis confidence. We found no statistical difference in the 
variables presented above between possible (19 patients), probable (16 patients) and definite groups 
 Master thesis –F. Desgranges  December 2012 
16 Bloodstream infections related to totally implantable venous access ports 
(4 patients) (data not shown). Nevertheless, this illustrates the difficulty of clearly defining PABSI 
retrospectively when local PAC infections signs were absent (24) or not documented, and when 
culture confirmation methods (such as quantitative cultures of catheter or blood or differential time 
to positivity summarized by Raad et al. (15)) are not done routinely which is the case of most Swiss 
hospitals. 
Our study is hampered by several limitations. The main ones are inherent to its retrospective design. 
Our data depend on reliability and quality of documentation in archived medical files. In 
consequence, we cannot exclude missing data or loss of important information. The external validity 
of our results was compromised as the study was conducted in one single hospital. However, this 
design may benefit from a better homogeneity of follow-up and retrospective data; moreover, it 
allows to assess local PAC –related practices by comparing PABSI rates in our institution with that 
reported in other studies. PABSI low incidence was another limitation of this study. Our nested case-
control study only included 78 patients in 2 years of follow-up, which may not have provided enough 
sensitivity to identify some risk factors. Moreover, comparisons made between cases and controls 
were considered as representative of the cohort, but would need confirmation by analyzing these 
factors in the whole cohort. Finally, follow-up time was inconsistent in the cohort, ranging from 16 to 
40 months and therefore missing PABSI that occurred after this limit. Nevertheless, we calculated a 
median time to PABSI of 179 days that was covered by the smallest follow-up duration.  
 
Conclusion 
PACs are considered as the safest long-term intravascular devices in terms of BSI rates. Our study 
demonstrated that local epidemiology and microbiology of PABSI in our institution was similar to 
previous reports. Risk factors for developing a CRBSI have been little investigated for PACs. Due to 
differences in carrying duration and system properties of PACs, they may be somewhat different to 
classical risk factors for invasive devices. Difficulties in defining universal risk factors between studies 
may be due to heterogeneous studied populations and emphasis the importance of local research. In 
our institution, we defined four independent predictive factors for PABSI. Neutropenia, diabetes 
mellitus and renal failure may cause decreased immunity and thus favor bloodstream infections. In 
consequence, particular attention should be paid to patients with such conditions. Development of 
another infection than PABSI is a mark of vulnerable patient’s state and may require further 
measures. Before updating any guidelines in our institution, it would be useful either to confirm 
these results or to test preventive measures in a larger prospective study. 
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